ClinicalTrials.gg
CompletedNCT02297594Updated Oct 20, 2015

Safety, Tolerability and PK Study of AK0529 in Healthy Human

A Phase 1 interventional study of AK0529 and Placebo in Respiratory Syncytial Virus Infections, sponsored by Shanghai Ark Biopharmaceutical Co., Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-20.

Sponsored by Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Respiratory Syncytial Virus Infections with a site in Australia — 1 open to participants now, 6 under way, 1 of them phase 3. Respiratory Syncytial Virus Infections · Australia.

Enrollment
31st of 44
74 · median 250
Started
2014
with 3 others
Phase 1
16 of 44
none open now
Registered
9th of 44
by date
Lead sponsor
3 of 44
Shanghai Ark Biopharmaceutical Co., Ltd.

Among the 44 studies in Respiratory Syncytial Virus Infections with a site in Australia, this one is the 31st largest by enrollment, is one of 4 that started in 2014, is one of 16 in phase 1, and was the 9th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 44 studies in Respiratory Syncytial Virus Infections with a site in Australia is open now. Recruiting first, the newest first:

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Respiratory Syncytial Virus Infections with a site in Australia, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability and PK of single and multiple ascending dose of AK0529 when administered orally in healthy subjects

Read the detailed description

This is a Phase 1, first-in-man, single-center, randomized, double blind, placebo controlled single and multiple ascending dose study in healthy male and female volunteers.

03

Conditions studied

  • Respiratory Syncytial Virus Infections
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be healthy males, or healthy females of non- or surgically sterilized or (amenorrhea for at least 1 year and confirmed by a follicle stimulating hormone [FSH] result of > 20 IU/mL).
  2. Must be aged 18 to 55 years of age inclusive.
  3. Must have (BMI) of 18.0 to 31.0 kg/m2 inclusive.
  4. Must have total body weight ≥50 kg at screening but ≤100 Kg.
  5. Must be willing and able to communicate and participate in the whole study.
  6. Must provide written .
  7. Must agree to use an adequate method of (as defined in Section 4.2.1).
  8. Must have , ALT, total , urea, creatinine and within the laboratory reference range at screening and Day -1.
  9. Must have \<450 ms, QTcB \<450 ms and PR interval \<210 ms for screening, Day -1 and pre-dose measurements, and not have any degree of heart block or conduction abnormality.
  10. Must have serology demonstrating they are free from infection with , , and (HIV-1 and HIV-2)

Exclusion criteria

Exclusion Criteria:

  1. Male subjects who have currently pregnant partners or who have partners planning to become pregnant during the duration of the study.
  2. Evidence or history of clinical significant oncological, pulmonary, chronic respiratory, hepatic, cardiovascular, hematological, metabolic, neurological, immunological, nephrological, endocrine or psychiatric disease, or current infection.
  3. (as decided by the investigator and the medical monitor) abnormalities in the (12 standard leads) including any degree of heart block, including asymptomatic bundle branch block.
  4. Family history of sudden death or of congenital prolongation of the or known congenital prolongation of the QTc interval or any clinical condition known to prolong the QTc interval.
  5. History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.
  6. Electrolyte disturbances, particularly hypokalemia hypocalcemia or hypomagnesemia.
  7. Any condition that could possibly affect drug absorption, e.g. gastrectomy or diarrhea.
  8. History of post-antibiotic colitis.
  9. History of any drug or alcohol abuse in the past 2 years prior to screening.
  10. Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = 400 mL beer, 25 mL of 40% spirit or a 75 mL glass of wine).
  11. Subjects who have a urine cotinine greater than 500 ng/mL at screening will be excluded. Subjects who are tobacco users (including smokers and users of snuff, chewing tobacco and other nicotine or nicotine-containing products) must have stopped use at least 90 days before screening.
  12. Receipt of an drug or participation in another clinical research study within 90 days prior to drug administration.
  13. Subjects who are study site employees, or immediate family members of a study site or sponsor employee.
  14. Subjects who have previously been enrolled and dosed in this study, except subjects undergoing repeat dosing in Cohort 4F (the fed PK cohort of the SAD part of the study).

Other protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    AK0529

    Generic name: AK0529 Dosage Form: capsule

    Drug: AK0529

  • Placebo comparator
    Placebo

    Sugar placebo

    Drug: Placebo

Interventions

  • DrugAK0529

    AK0529 capsule for oral administration

    Also known as: AK0529 capsule

  • DrugPlacebo

    Sugar placebo capsule for oral administration

    Also known as: Sugar placebo capsule

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events, serious adverse events

    Time frame: Screening to Day 14 - 21

Secondary outcomes

  1. Pharmacokinetics of single dose study: Area Under Curve (AUC)

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose

  2. Pharmacokinetics of single dose study: Observed Maximum plasma concentration (Cmax)

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose

  3. Pharmacokinetics of single dose study: half-life (t1/2)

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose

  4. Pharmacokinetics of single dose study: time to maximum plasma concentration (tmax)

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose

  5. Pharmacokinetics of single dose study: Volume of distribution

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose

  6. Pharmacokinetics of single dose study: Clearance

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose

  7. Pharmacokinetics of multiple dose study:Area Under Curve (AUC)

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 hours post-dose on Day1 and pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 hours post-dose on Day 7 and at 24 hours (Day 8) and at 48 hours (Day 9)

  8. Pharmacokinetics of multiple dose study: Observed Maximum plasma concentration (Cmax)

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 hours post-dose on Day1 and pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 hours post-dose on Day 7 and at 24 hours (Day 8) and at 48 hours (Day 9)

  9. Pharmacokinetics of multiple dose study: half-life (t1/2)

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 hours post-dose on Day1 and pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 hours post-dose on Day 7 and at 24 hours (Day 8) and at 48 hours (Day 9)

  10. Pharmacokinetics of multiple dose study: time to maximum plasma concentration (tmax)

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 hours post-dose on Day1 and pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 hours post-dose on Day 7 and at 24 hours (Day 8) and at 48 hours (Day 9)

  11. Pharmacokinetics of multiple dose study:Volume of distribution

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 hours post-dose on Day1 and pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 hours post-dose on Day 7 and at 24 hours (Day 8) and at 48 hours (Day 9)

  12. Pharmacokinetics of multiple dose study: clearance

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 hours post-dose on Day1 and pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 hours post-dose on Day 7 and at 24 hours (Day 8) and at 48 hours (Day 9)

07

Study locations

1 site
  • Q-Pharm Pty Ltd QIMR Berghofer & Royal Brisbane and Women's Hospital Campus
    Brisbane, Queensland 4006, Australia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2014
First posted
Nov 21, 2014
Start
Oct 2014
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Last update
Oct 20, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02297594
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Nov 21, 2014
Start date
Oct 2014
Primary completion
Jun 2015
Completion
Jun 2015
Last update
Oct 20, 2015

Study contacts

Paul Griffin, MD
principal investigator · Q-Pharm Pty Ltd

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziresovir

Start the discussion